Eli Lilly to double Mounjaro production

Analysts have returned from a visit to the drugmaker’s Indianapolis headquarters, reporting that Lilly is facing a number of headwinds, one of which will be warded off by doubling the firm’s production capacity for Mounjaro.
by ulrich quistgaard, translated by daniel pedersen

In an attempt to mitigate future financial challenges, Eli Lilly will double the production of its newest and highly sought-after type 2 diabetes drug, Mounjaro, reports industry media Endpoints News.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading